만성 외상성 뇌병증 시장 보고서(2025년)
Chronic Traumatic Encephalopathy Global Market Report 2025
상품코드 : 1764285
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

만성 외상성 뇌병증 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 2029년에는 CAGR8.5%를 나타내 21억 달러로 성장할 전망입니다. 이 기간의 주요 동향으로는 바이오 마커에 의한 진단의 진보, 조기 발견을 위한 화상 진단 기술의 향상, 질환 수식 치료의 개발, 웨어러블 충격 모니터링 기기의 혁신, 선수 스크리닝 이니셔티브에 수반하는 사회 의식의 향상 등을 들 수 있습니다.

두부 외상 증가는 미래의 만성 외상성 뇌병증 시장의 성장을 가속할 것으로 예측됩니다. 증가는 충돌이나 사고로 인한 외상성 뇌 손상의 위험을 높이는 충격이 큰 스포츠에 참가하는 개인 증가로 인한 곳이 큽니다. 이 축적은 뇌세포를 서서히 손상시키고 인지기능의 저하나 감정적인 문제를 일으킵니다. 예를 들어, 2024년 11월 미국 정부 기관인 테네시주 보건부는 2023년에 외상성 뇌손상(TBI) 레지스트리에 포함될 자격이 있는 환자가 8,196명으로 2022년에 비해 2.4% 증가했다고 보고했습니다.

만성 외상성 뇌병증 시장의 주요 기업은 임상 검사를 신속하게 하고 혁신적인 진단·치료 옵션을 보다 효과적으로 제공하기 위해 자회사를 설립하는 등 선진적인 전략을 채용하게 되어 왔습니다. 예를 들어 미국의 생명공학기업인 세라퓨틱 솔루션즈 인터내셔널은 2023년 5월 JadiCell 만능성체 줄기세포를 이용한 만성 외상성 뇌병증(CTE) 치료의 임상 데이터와 치료 Biologics Inc.를 설립했습니다. 이 자회사는 선수와 퇴역 군인이 자주 앓고있는 신경 퇴행성 질환인 CTE에 대한 JadiCell을 이용한 치료를 추진하는 데 전념하고 있으며 기존 임상 데이터와 FDA와의 지속적인 규제 당국과의 관계를 활용하여 현재 치료 불가능한 질병에 대한 공식적인 임상 검사를 시작할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

KTH
영문 목차

영문목차

Chronic traumatic encephalopathy (CTE) is a neurological disorder caused by repeated head injuries over an extended period. It affects memory, cognitive abilities, and emotional regulation, resulting in confusion, mood fluctuations, and challenges in carrying out daily activities, often manifesting years after the initial injury.

The primary treatment methods for chronic traumatic encephalopathy include pharmacological therapies, rehabilitation programs, psychological support, surgical procedures, and alternative approaches. Pharmacological treatments involve using drugs such as anti-inflammatory agents and antidepressants to alleviate symptoms, decrease brain inflammation, and enhance daily functioning. Diagnosis is conducted through various methods including imaging scans, neurological assessments, biomarker analysis, among others. The condition is categorized into early-stage and advanced-stage CTE and is managed by different users such as hospitals, clinics, and research organizations.

The chronic traumatic encephalopathy market research report is one of a series of new reports from The Business Research Company that provides chronic traumatic encephalopathy market statistics, including the chronic traumatic encephalopathy industry global market size, regional shares, competitors with the chronic traumatic encephalopathy market share, detailed chronic traumatic encephalopathy market segments, market trends, opportunities, and any further data you may need to thrive in the chronic traumatic encephalopathy industry. This chronic traumatic encephalopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic traumatic encephalopathy market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period is due to greater awareness of sports-related head injuries, increased involvement in contact sports, a surge in military-related traumatic brain injuries, expanded research on neurodegenerative diseases, and improved access to diagnostic technologies.

The chronic traumatic encephalopathy market size is expected to see strong growth in the next few years. It will grow to $2.10 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth projected for the forecast period is driven by increasing investments in neuroscience research, a rising demand for advanced diagnostic imaging, heightened emphasis on player safety regulations, expanding clinical studies on brain injuries, and growing public awareness about long-term brain health. Key trends during this period include progress in biomarker-based diagnostics, improved imaging techniques for early detection, development of disease-modifying treatments, innovations in wearable impact monitoring devices, and enhanced public awareness along with athlete screening initiatives.

The increasing number of head injuries is expected to drive growth in the chronic traumatic encephalopathy market in the future. Head injuries involve physical harm to the scalp, skull, or brain caused by an external impact or force. This rise in head injuries is largely due to more individuals participating in high-impact sports, which heightens the risk of traumatic brain injuries from collisions and accidents. Chronic traumatic encephalopathy (CTE) results from repeated head injuries that lead to the buildup of abnormal tau protein in the brain. This buildup progressively damages brain cells, causing cognitive decline and emotional issues. For example, in November 2024, the Tennessee Department of Health, a US government agency, reported that in 2023, 8,196 patients qualified for inclusion in the traumatic brain injury (TBI) Registry, representing a 2.4% increase from 2022. Thus, the growing occurrence of head injuries is fueling the expansion of the chronic traumatic encephalopathy market.

Leading companies in the chronic traumatic encephalopathy market are increasingly adopting advanced strategies, such as creating subsidiary companies, to speed up clinical trials and more effectively deliver innovative diagnostic and treatment options. A subsidiary is a separate legal entity owned or controlled by a parent company, which typically holds over 50% of its voting shares. This arrangement allows the parent company to enter new markets, reduce risks, and focus on specialized areas like research and development (R&D) or regional expansion. For example, in May 2023, Therapeutic Solutions International, a US biotechnology firm, established CTE Biologics Inc., a subsidiary to commercialize its clinical data and investigational new drug (IND) application for chronic traumatic encephalopathy (CTE) treatment using JadiCell universal adult stem cells. This subsidiary is dedicated to advancing JadiCell-based therapies for CTE-a neurodegenerative disorder commonly affecting athletes and military veterans-leveraging existing clinical data and ongoing regulatory engagement with the FDA to potentially begin formal clinical trials for this currently untreatable disease.

In March 2025, Enigma Biomedical USA Inc., a US biotechnology firm, collaborated with Boston University's chronic traumatic encephalopathy (CTE) center and the Concussion Legacy Foundation to promote early detection of CTE using advanced imaging techniques. This partnership focuses on validating 4R tau PET imaging biomarkers to enhance understanding and facilitate early diagnosis of CTE in living patients. The Concussion Legacy Foundation (CLF) is a US nonprofit organization, while the Boston University CTE Center is a US-based institution conducting cutting-edge research on chronic traumatic encephalopathy.

Major players in the chronic traumatic encephalopathy market are MedStar Health, NorthShore University Health System, Boston University, Mayo Foundation for Medical Education and Research, Craig Hospital, Quanterix Corporation, Life Molecular Imaging GmbH, Prothena Corporation plc, Annovis Bio Inc., Noveome Biotherapeutics Inc., Therapeutic Solutions International Inc., Kannalife Sciences Inc., Wund Healing Biopharmaceuticals, The Regents of The University of California, Novoron Bioscience Inc., FibroGenesis LLC, AgoneX Biopharmaceuticals Inc., Nexien Biopharma Inc., PresSura Neuro, and The Stern Lab.

North America was the largest region in the chronic traumatic encephalopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic traumatic encephalopathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic traumatic encephalopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic traumatic encephalopathy market consists of revenues earned by entities by providing services such as personalized medicine planning, telemedicine, genetic testing, occupational therapy, mental health support, cognitive therapy, and patient monitoring. The market value includes the value of related products and medical devices sold by the service providers or included within the service offering. The chronic traumatic encephalopathy market also includes sales of wearable health monitoring devices, brain imaging equipment, neuroprotective supplements, and biomarker assay kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Traumatic Encephalopathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic traumatic encephalopathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for chronic traumatic encephalopathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic traumatic encephalopathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Chronic Traumatic Encephalopathy Market Characteristics

3. Chronic Traumatic Encephalopathy Market Trends And Strategies

4. Chronic Traumatic Encephalopathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Chronic Traumatic Encephalopathy Growth Analysis And Strategic Analysis Framework

6. Chronic Traumatic Encephalopathy Market Segmentation

7. Chronic Traumatic Encephalopathy Market Regional And Country Analysis

8. Asia-Pacific Chronic Traumatic Encephalopathy Market

9. China Chronic Traumatic Encephalopathy Market

10. India Chronic Traumatic Encephalopathy Market

11. Japan Chronic Traumatic Encephalopathy Market

12. Australia Chronic Traumatic Encephalopathy Market

13. Indonesia Chronic Traumatic Encephalopathy Market

14. South Korea Chronic Traumatic Encephalopathy Market

15. Western Europe Chronic Traumatic Encephalopathy Market

16. UK Chronic Traumatic Encephalopathy Market

17. Germany Chronic Traumatic Encephalopathy Market

18. France Chronic Traumatic Encephalopathy Market

19. Italy Chronic Traumatic Encephalopathy Market

20. Spain Chronic Traumatic Encephalopathy Market

21. Eastern Europe Chronic Traumatic Encephalopathy Market

22. Russia Chronic Traumatic Encephalopathy Market

23. North America Chronic Traumatic Encephalopathy Market

24. USA Chronic Traumatic Encephalopathy Market

25. Canada Chronic Traumatic Encephalopathy Market

26. South America Chronic Traumatic Encephalopathy Market

27. Brazil Chronic Traumatic Encephalopathy Market

28. Middle East Chronic Traumatic Encephalopathy Market

29. Africa Chronic Traumatic Encephalopathy Market

30. Chronic Traumatic Encephalopathy Market Competitive Landscape And Company Profiles

31. Chronic Traumatic Encephalopathy Market Other Major And Innovative Companies

32. Global Chronic Traumatic Encephalopathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Traumatic Encephalopathy Market

34. Recent Developments In The Chronic Traumatic Encephalopathy Market

35. Chronic Traumatic Encephalopathy Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기